Combining top-ranked immunotherapeutics in lung cancer
Mené sur 23 patients atteints d'un cancer du poumon non à petites cellules de stade métastatique, cet essai non randomisé de phase Ib évalue la dose maximale tolérée et la toxicité d'un composé appelé ALT-803, un super agoniste de IL-15, dispensé par voie sous-cutanée et utilisé en combinaison avec le nivolumab dispensé par voie intraveineuse
Immunotherapy is becoming widely used in the treatment of non-small-cell lung cancer (NSCLC) in light of its impressive results in both first-line and second-line settings.1 However, doctors need to accept that not all patients can be treated with this approach and much still remains to be done to improve outcomes for patients with this lethal disease. Combining new immunotherapeutic agents with existing treatments such as chemotherapy or tyrosine kinases inhibitors can have both good and bad consequences.
The Lancet Oncology , commentaire, 2017